Tarsons Products' Credit Rating Reaffirmed by CARE

CARE Ratings has reaffirmed Tarsons Products Limited's credit ratings for its bank loan facilities, confirming the company's financial stability and continued access to credit.

Key Rating Decisions

The company's long-term bank facilities, totaling ₹500.73 crore, maintain their 'CARE A; Stable' rating. This figure is a slight decrease from the previously assigned ₹516.02 crore.

Additionally, Tarsons' short-term borrowing capacity has been strengthened. A new short-term bank facility of ₹4.00 crore has been assigned a 'CARE A1' rating. An existing short-term facility has seen a significant enhancement to ₹84.00 crore, up from ₹39.00 crore, and has also been reaffirmed with a 'CARE A1' rating. Ratings for combined long-term/short-term facilities were also reaffirmed at ₹24.00 crore ('CARE A; Stable / CARE A1').

Significance of the Ratings

Credit ratings are a key indicator of a company's financial health and its capacity to repay debt. The 'CARE A; Stable' rating suggests a lower risk profile for lenders, which can translate into more favorable borrowing costs for Tarsons Products.

This reaffirmation signals that CARE Ratings views the company's financial position and debt management practices positively. For stakeholders, this implies continued financial stability and a positive outlook on debt management, supporting the company's reputation and confidence among investors and partners. The expansion and addition of short-term facilities further provide greater financial flexibility for managing working capital and immediate needs.

Company Background

Tarsons Products is a prominent Indian manufacturer of labware, offering a diverse product range and exporting to over 40 countries.

In June 2025, CARE had previously reaffirmed Tarsons' ratings, noting operational improvements and a recovery in operating margins during the second half of FY25. The company reported FY25 revenues of ₹402.41 crore.

Currently, Tarsons is undertaking a substantial capital expenditure (capex) program of approximately ₹800 crore, scheduled for completion by FY26. This investment is funded through IPO proceeds, internal accruals, and term loans.

Previously, in January 2024, CARE had placed the company's ratings on watch due to an acquisition of foreign entities; this matter has since been resolved.

Potential Risks

Despite the stable credit rating reaffirmation, Tarsons faces risks identified by CARE, including susceptibility to raw material price fluctuations, a lengthy working capital cycle, and implementation risks associated with its large capex program.

Furthermore, recent analyst reports from MarketsMojo (February-March 2026) have issued 'Sell' and 'Strong Sell' ratings for Tarsons. These reports cite deteriorating financial performance, multiple quarters of negative profit after tax (PAT), a declining return on capital employed (ROCE), and bearish technical indicators, presenting a contrasting view of the company's short-term prospects.

Industry Comparison

Tarsons Products is a notable player in India's labware sector, alongside competitors such as Poly Medicure and Fischer Medical. While Poly Medicure reports a ROCE of 20.08%, Tarsons' ROCE stood at 6.68% for FY25, highlighting a potential difference in capital efficiency compared to some peers.

Key Financial Metrics

• Tarsons Products' FY25 revenue was ₹402.41 crore (Standalone).
• The company's ROCE was 6.68% in FY25 (Consolidated).
• Overall gearing was 0.61x as of March 31, 2025 (Consolidated).

What to Track Next

Investors should monitor future credit reviews by CARE Ratings and any changes in outlook. The successful completion and operationalization of the ₹800 crore capex project and its impact on revenue and profitability will be critical. Management's strategies to improve working capital efficiency and manage raw material price volatility are also important. Performance against analyst expectations, particularly concerning profitability and ROCE given recent downgrades, will be closely watched.